China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $7.23M
• Dividend Yield: N/A
• Average Volume (3M): 41.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -26.92%
• EPS Growth: 69.90%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 5,022,002
• 10 Day Avg. Volume: 15,303
• 30 Day Avg. Volume: 41,022
• PEG Ratio: 1.25
• Price to Book (P/B): 5.25
• Price to Sales (P/S): 8.98
• P/FCF Ratio: -53.68
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▲(11.11% Upside)

China Pharma Holdings faces significant financial challenges, with negative profitability and cash flow metrics being the most impactful factors. The technical analysis suggests a bearish trend, but the stock is nearing oversold conditions. Valuation metrics are unattractive due to negative earnings. The recent patent acquisition is a positive strategic move, but it does not outweigh the financial distress. Overall, the stock score reflects these challenges and opportunities.

Positive Factors

Patent Acquisition

The acquisition of a patent for Captopril microcapsules enhances the company's pharmaceutical portfolio, potentially strengthening its market position and product offerings in the long term.

Moderate Debt Levels

A moderate debt-to-equity ratio indicates manageable leverage, providing the company with some financial flexibility to invest in growth opportunities without overburdening its balance sheet.

Revenue Growth

Significant revenue growth suggests increased market demand and successful sales strategies, which can support future profitability if operational efficiencies improve.

Negative Factors

Negative Profitability

Negative profitability indicates operational inefficiencies and challenges in converting revenue into profit, which could hinder long-term financial stability and growth.

Severe Financial Distress

An extremely negative ROE highlights severe financial distress, suggesting that the company is not generating sufficient returns on shareholder equity, which could impact investor confidence and future capital raising.

Poor Cash Flow

Negative cash flows indicate poor cash generation, which can strain the company's ability to fund operations and growth initiatives, potentially leading to liquidity issues if not addressed.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

How the Company Makes Money

China Pharma Holdings generates revenue through the sale of its pharmaceutical products, which include both prescription medications and over-the-counter drugs. The company's primary revenue streams stem from the sale of its proprietary drugs, which are developed in-house, as well as from partnerships with other pharmaceutical firms for the licensing and distribution of generic medications. Additionally, CPHI may benefit from government contracts and subsidies aimed at boosting local pharmaceutical production and innovation. The company also looks to expand its market presence through strategic collaborations and joint ventures, which can enhance its distribution capabilities and market reach.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings is facing significant financial challenges, with negative profitability and cash flow metrics. Despite revenue growth, profitability remains elusive. The balance sheet shows manageable debt, but the extremely negative ROE highlights severe financial distress.

Income Statement

The income statement shows significant challenges with negative margins across the board. The TTM data indicates a gross profit margin of -11.97% and a net profit margin of -69.14%, reflecting substantial losses. Revenue growth is positive at 66.55% TTM, but this is overshadowed by the negative profitability metrics. The company is struggling to convert revenue into profit, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.53 TTM, which is a positive aspect. However, the return on equity is extremely negative at -113,408.71% TTM, indicating severe losses relative to shareholder equity. The equity ratio is not explicitly calculated, but the high negative ROE suggests significant financial instability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a free cash flow growth rate of -89,093,826.35% TTM, indicating worsening cash flow conditions. The operating cash flow to net income ratio is low at 0.08 TTM, suggesting poor cash generation relative to net losses. The free cash flow to net income ratio is slightly better at 0.17 TTM, but still reflects financial distress.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	756.22B	4.53M	7.01M	8.10M	9.64M	10.87M
Gross Profit	-59.65B	-1.99M	-281.08K	-493.92K	349.27K	1.95M
EBITDA	378.77B	-1.96M	8.44K	-837.69K	230.34K	106.85K
Net Income	-651.48B	-4.74M	-3.08M	-3.97M	-3.40M	-2.87M
Balance Sheet
Total Assets	15.98M	14.89M	16.47M	17.78M	22.65M	21.12M
Cash, Cash Equivalents and Short-Term Investments	294.32K	626.88K	1.42M	2.03M	4.86M	957.65K
Total Debt	3.57M	3.59M	4.63M	8.76M	12.49M	7.43M
Total Liabilities	7.49M	7.14M	9.01M	13.49M	16.63M	13.11M
Stockholders Equity	8.49M	7.75M	7.45M	4.29M	6.02M	8.00M
Cash Flow
Free Cash Flow	-129.61K	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
Operating Cash Flow	234.75K	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
Investing Cash Flow	-404.34K	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
Financing Cash Flow	-214.63K	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Negative. The current price of 1.35 is below the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.67, and below the 200-day MA of 1.82, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 33.54 is Neutral, neither overbought nor oversold. The STOCH value of 11.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	51 Neutral	$2.07M	―	2.66%	―	-27.81%	―
SNOA	50 Neutral	$5.75M	-1.62	-76.14%	―	25.02%	55.11%
EVOK	46 Neutral	$18.95M	-4.62	-134.88%	―	67.40%	78.51%
CPHI	45 Neutral	$7.23M	-1.31	-42.47%	―	-26.92%	69.90%
SBFM	44 Neutral	$6.77M	-0.75	-24.34%	―	13.24%	98.80%

China Pharma Holdings Corporate Events

China Pharma Holdings Acquires Patent in Stock Deal

On December 4, 2025, China Pharma Holdings‘ subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Lijie Tang for the acquisition of an invention patent on Captopril microcapsules. The transfer, valued at $6.3 million, will be compensated through the issuance of 3,500,000 shares of the company’s common stock, highlighting a strategic move to enhance its pharmaceutical offerings.